Acetyl-HSP90AA1 (K292/284) Antibody

What is HSP90AA1 and why is its acetylation at K292/284 significant?

HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1) is an inducible molecular chaperone that functions as a homodimer, aiding in the proper folding of specific target proteins through ATPase activity modulated by co-chaperones . The acetylation at lysine residues 292/284 represents a critical post-translational modification that regulates HSP90's function. This specific acetylation site affects HSP90's interaction with client proteins and co-chaperones, potentially altering its chaperone activity and downstream signaling pathways . Research has shown that acetylation status at K292/284 may influence HSP90's role in cancer progression, immune responses, and therapeutic resistance .

How does Acetyl-HSP90AA1 (K292/284) differ from general HSP90 antibodies in research applications?

Acetyl-HSP90AA1 (K292/284) antibodies specifically detect HSP90 protein only when acetylated at lysine residues 292/284, providing a targeted approach to studying this post-translational modification . Unlike general HSP90 antibodies that recognize total HSP90 protein regardless of modification status, these acetyl-specific antibodies enable researchers to:

• Distinguish between acetylated and non-acetylated forms of HSP90

• Study dynamic changes in HSP90 acetylation under various experimental conditions

• Investigate the specific role of K292/284 acetylation in cellular processes

• Correlate acetylation status with functional outcomes in disease models

This specificity makes these antibodies invaluable for researchers studying the regulatory mechanisms and functional consequences of HSP90 acetylation.

Experimental Applications and Techniques

Verifying antibody specificity is crucial for reliable results. Several approaches are recommended:

• Positive control validation: Use cell lysates treated with HDAC inhibitors (e.g., Trichostatin A, LBH589) to increase HSP90 acetylation levels . Compare with untreated cells to confirm increased signal.

• Peptide competition assay: Pre-incubate the antibody with the acetylated immunizing peptide before application to your samples. This should abolish specific binding, while pre-incubation with non-acetylated peptide should not affect binding .

• Knockout/knockdown controls: Compare signals between wild-type cells and HSP90AA1 knockout/knockdown cells. Complete absence of signal in knockout cells confirms specificity, as demonstrated in validation studies using HSP90AA1 knockout HEK-293T cell lines .

• Acetylation-site mutants: Express HSP90AA1 with K292/284 mutated to arginine (which cannot be acetylated) and compare to wild-type protein. The antibody should not detect the mutant form.

• Parallel detection: Compare results with general HSP90 antibodies to ensure that the acetyl-specific antibody is detecting a subset of the total HSP90 population .

How does HSP90 acetylation at K292/284 influence its role in cancer progression and immunotherapy resistance?

HSP90 acetylation at K292/284 represents a critical regulatory mechanism in cancer progression and therapy resistance. Research has identified several key pathways:

• NANOG-TCL1A-AKT axis: HSP90AA1 has been identified as a NANOG transcriptional target, and HSP90A potentiates AKT activation through TCL1A stabilization. This contributes to multi-aggressive properties in NANOG-high tumor cells, including resistance to immunotherapy .

• Immune evasion: HSP90A inhibition can reverse multi-modal resistance in immune-edited tumor cells, sensitizing immune-refractory tumors to adoptive T cell transfer and PD-1 blockade. This suggests that acetylated HSP90 may contribute to immune evasion mechanisms .

• Cancer stem cell-like properties: HSP90A upregulation has been associated with cancer stem cell-like phenotypes and multi-modal resistance. siRNA-mediated knockdown of HSP90AA1 re-sensitized resistant cancer cells to both immunotherapy and chemotherapy .

• Extracellular roles: Acetylated HSP90α can be secreted extracellularly, where it may promote tumor cell invasion. Anti-acetylated HSP90α antibodies have been shown to inhibit in vitro invasion by tumor cells, suggesting therapeutic potential .

The acetylation status at K292/284 appears to be a regulatory switch that modulates HSP90's interactions with client proteins involved in these pathways, making it an attractive target for cancer therapy research .

What role does HSP90AA1 acetylation play in NAT10-mediated ac4C RNA modification in cancer?

Recent research has uncovered a novel mechanism involving NAT10-mediated mRNA ac4C (N4-acetylcytidine) modification of HSP90AA1 in regulating metastasis and tumor resistance in hepatocellular carcinoma (HCC) under endoplasmic reticulum stress (ERS) . Key findings include:

• NAT10 silencing downregulates ac4C modifications in the CDS coding region of the HSP90AA1 gene, as demonstrated by acRIP-Seq and RNA-Seq data integration .

• The acetylation and expression of HSP90AA1 gene are significantly correlated with NAT10 gene expression, particularly in the context of endoplasmic reticulum stress .

• Analysis of the ac4C peak showed the typical CXX motif, confirming the quality of the acRIP-Seq analysis. The expression level of HSP90AAA1 ac4C modification decreased after the knockdown of NAT10 gene expression .

• The ac4C peak of HSP90AA1 showed significantly increased enrichment in the ERS IP group compared to si-NAT10 IP, suggesting a regulatory role for NAT10 in HSP90AA1 acetylation under stress conditions .

This represents an emerging area of research connecting RNA modifications, protein acetylation, and cancer progression, offering new perspectives on HSP90 regulation beyond its protein-level modifications.

What are the critical factors for successful detection of acetylated HSP90AA1 in Western blot experiments?

Successfully detecting acetylated HSP90AA1 in Western blot experiments requires attention to several critical factors:

• Sample preparation:

  • Use fresh samples whenever possible

  • Include protease and deacetylase inhibitors (e.g., TSA, nicotinamide) in lysis buffers to preserve acetylation status

  • Avoid repeated freeze-thaw cycles that may affect protein modifications

• Protein loading and transfer:

  • Load sufficient protein (20-40 μg) per lane to detect potentially low-abundance acetylated forms

  • Ensure complete transfer to membrane, particularly for higher molecular weight proteins like HSP90 (90 kDa)

• Blocking and antibody incubation:

  • BSA is often preferred over milk for phospho- and acetyl-specific antibodies (milk contains casein which can interact with phospho-specific antibodies)

  • Optimize primary antibody dilution (typically 1:500-1:2000) and incubation time (overnight at 4°C recommended)

  • Use high-quality secondary antibodies with minimal cross-reactivity

• Detection system optimization:

  • For fluorescence-based systems, IRDye® 800CW and 680RD-conjugated secondary antibodies have shown good results at 1:20,000 dilution

  • For chemiluminescence, enhanced ECL reagents may be necessary for optimal sensitivity

• Controls:

  • Include loading controls (e.g., GAPDH) on the same blot

  • Use HEK-293T cells treated with HDAC inhibitors as positive controls

  • Consider using HSP90AA1 knockout cell lysates as negative controls

How can I optimize immunohistochemistry protocols for Acetyl-HSP90AA1 (K292/284) detection in tissue samples?

Optimizing immunohistochemistry for Acetyl-HSP90AA1 (K292/284) detection requires careful attention to several methodological aspects:

• Tissue fixation and processing:

  • Formalin-fixed, paraffin-embedded (FFPE) tissues show good results with these antibodies

  • Fixation time should be optimized to preserve epitope accessibility while maintaining tissue morphology

• Antigen retrieval methods:

  • Heat-mediated antigen retrieval is critical for exposing the acetylated epitope

  • EDTA buffer (pH 8.0) has shown superior results compared to citrate buffer for HSP90 antibodies

  • Antigen retrieval time and temperature should be optimized (typically 95-100°C for 15-20 minutes)

• Blocking and antibody parameters:

  • Use 10% goat serum for effective blocking to reduce background

  • Recommended antibody dilution range: 1:100-1:300

  • Overnight incubation at 4°C typically yields optimal results

• Detection system:

  • Streptavidin-Biotin-Complex (SABC) with DAB chromogen works effectively

  • Biotinylated secondary antibodies at appropriate dilutions (typically incubated for 30 minutes at 37°C)

• Counterstaining and controls:

  • Light hematoxylin counterstaining preserves visibility of DAB signal

  • Include positive control tissues (mouse or rat testis tissue has shown reliable expression)

  • Include negative controls (primary antibody omitted) to assess background

• Validation:

  • Compare staining patterns with total HSP90 antibodies to confirm localization patterns

  • Consider dual immunofluorescence with markers of relevant compartments to confirm subcellular localization

How can Acetyl-HSP90AA1 (K292/284) antibodies be used to study the effects of HSP90 inhibitors in cancer therapy research?

Acetyl-HSP90AA1 (K292/284) antibodies provide valuable tools for studying HSP90 inhibitors' mechanisms and efficacy in cancer therapy research:

• Monitoring target engagement:

  • Track changes in HSP90 acetylation status following inhibitor treatment to confirm direct effects on the target protein

  • Correlate acetylation changes with functional outcomes (e.g., client protein degradation)

• Mechanism of action studies:

  • Investigate whether HSP90 inhibitors (e.g., AUY-922, Luminespib) affect HSP90 acetylation as part of their mechanism

  • Determine whether acetylation status affects inhibitor binding or efficacy

• Combination therapy research:

  • Assess how HSP90 inhibition combined with immunotherapy affects HSP90 acetylation patterns

  • Research shows HSP90 inhibition can sensitize immune-refractory tumors to adoptive T cell transfer and PD-1 blockade

• Resistance mechanisms:

  • Compare HSP90 acetylation patterns between inhibitor-sensitive and inhibitor-resistant cells

  • Determine whether altered acetylation contributes to resistance development

• Biomarker development:

  • Evaluate whether HSP90 acetylation status could serve as a predictive biomarker for response to HSP90 inhibitors

  • Correlate baseline acetylation levels with treatment outcomes in preclinical models

The antibodies enable precise monitoring of HSP90 acetylation in various experimental conditions, contributing to better understanding of HSP90 inhibitor pharmacodynamics and potential combination strategies to overcome resistance .

What methods can be used to study extracellular acetylated HSP90AA1 and its role in the tumor microenvironment?

Studying extracellular acetylated HSP90AA1 requires specialized techniques to detect and characterize this form in the tumor microenvironment:

• Collection and preparation of extracellular samples:

  • Collect conditioned media from cell cultures under serum-free conditions

  • Use ultracentrifugation or size-exclusion filtration to concentrate secreted proteins

  • Consider isolating exosomes, which may contain HSP90

• Detection methods:

  • ELISA: Develop sandwich ELISA using capture antibodies against HSP90 and detection with Acetyl-HSP90AA1 (K292/284) antibodies

  • Western blot of concentrated conditioned media or extracellular vesicle preparations

  • Immunofluorescence staining of non-permeabilized cells to detect surface-associated HSP90

• Functional studies:

  • Invasion assays with addition of purified acetylated HSP90 or blocking antibodies

  • Co-culture systems to study interactions between tumor cells and stromal components mediated by acetylated HSP90

  • Research has shown anti-acetylated HSP90α antibodies can inhibit in vitro invasion by tumor cells

• Visualization in tissue context:

  • Immunohistochemistry optimized for extracellular protein detection (minimal permeabilization)

  • Multiplex immunofluorescence to co-localize acetylated HSP90 with extracellular matrix components

• In vivo models:

  • Analyze tumor interstitial fluid for presence of acetylated HSP90

  • Consider using in vivo imaging with labeled antibodies to track extracellular HSP90 localization

Confocal microscopy has been successfully employed to visualize acetylated HSP90 localization in MDA-MB-231 cells under serum-free conditions with or without HDAC inhibitor treatment, demonstrating the utility of these approaches for studying extracellular HSP90 .

How is acetylation of HSP90AA1 linked to metabolic reprogramming in cancer cells?

Recent research has begun to uncover connections between HSP90 acetylation and metabolic reprogramming in cancer cells:

• Glycolytic regulation: HSP90 inhibition leads to blockade of glycolytic flux in head and neck squamous cell carcinoma (HNSCC) cells by simultaneously suppressing PKM2 and PFKP at both the transcriptional and post-translational levels . While the specific role of K292/284 acetylation in this process is still being investigated, this highlights HSP90's involvement in cancer metabolism.

• Molecular interfaces: HSP90A appears to be at the crossroads between NANOG-TCL1A axis and multi-aggressive properties of immune-edited tumor cells . This positioning suggests it may integrate metabolic signals with other cancer-promoting pathways.

• AKT pathway integration: HSP90A potentiates AKT activation through TCL1A-stabilization , and the AKT pathway is a known regulator of cancer metabolism. Changes in HSP90 acetylation status may influence this signaling axis and thereby affect metabolic reprogramming.

• Stress response coordination: As a molecular chaperone, HSP90 helps cells adapt to various stresses. Under endoplasmic reticulum stress conditions, NAT10-mediated mRNA ac4C modification of HSP90AA1 has been implicated in tumor resistance , suggesting a role in coordinating stress responses with metabolic adaptation.

• Mitochondrial function: HSP90 plays a critical role in mitochondrial import, delivering preproteins to the mitochondrial import receptor TOMM70 . Alterations in HSP90 acetylation may affect this function, potentially influencing mitochondrial metabolism in cancer cells.

This emerging area presents opportunities for researchers to investigate how HSP90 acetylation status influences metabolic enzymes and pathways in different cancer contexts.

What are the technical challenges in developing site-specific acetylation antibodies for HSP90AA1, and how might these be overcome?

Developing highly specific antibodies against acetylated K292/284 in HSP90AA1 presents several technical challenges:

• Epitope specificity issues:

  • Sequence similarity between HSP90AA1 and HSP90AB1 isoforms around the acetylation site can lead to cross-reactivity

  • The acetylated lysine must be recognized in its precise protein context for true specificity

  • Solution: Use carefully designed synthetic peptides with acetyl-lysine incorporated at the specific position, and perform extensive cross-reactivity testing against related sequences

• Validation complexity:

  • Current validation methods may not definitively prove acetyl-site specificity

  • Western blotting results are sometimes not definitive for demonstrating specificity, as noted in some product information

  • Solution: Implement comprehensive validation using acetylation site mutants, mass spectrometry confirmation, and CRISPR-engineered cell lines

• Low abundance challenges:

  • Acetylated forms may represent a small fraction of total HSP90, making detection difficult

  • Solution: Develop enrichment strategies (e.g., immunoprecipitation with acetyl-lysine antibodies prior to detection) and more sensitive detection methods

• Contextual variability:

  • Acetylation may occur in context-dependent patterns that affect epitope accessibility

  • Solution: Develop antibodies against different regions surrounding the acetylation site and validate in multiple experimental contexts

• Future directions:

  • Development of conformation-specific antibodies that recognize acetylation-induced structural changes

  • Creating recombinant antibody fragments with enhanced specificity

  • Applying phage display technology to select high-affinity binders to the acetylated epitope

Overcoming these challenges will enable more precise studies of HSP90 acetylation dynamics and their functional consequences in various physiological and pathological conditions.

How should researchers design experiments to distinguish between different post-translational modifications of HSP90AA1?

Designing experiments to distinguish between different post-translational modifications (PTMs) of HSP90AA1 requires a systematic approach:

• Multi-antibody strategy:

  • Use specific antibodies for different modifications (acetylation, phosphorylation, ubiquitination, etc.)

  • Run parallel immunoblots of the same samples with different modification-specific antibodies

  • Consider reprobing membranes when possible after sufficient stripping to confirm signals are from the same protein

• Sequential immunoprecipitation approach:

  • First immunoprecipitate with an antibody against one modification

  • Then probe the immunoprecipitate with antibodies against other modifications

  • This has been successfully applied for acetylated HSP90 using acetyl lysine agarose beads followed by specific antibody detection

• Mass spectrometry-based validation:

  • Liquid chromatography-tandem mass spectrometry (LC-MS/MS) can definitively identify and quantify multiple PTMs simultaneously

  • This approach was used to detect total ac4C modification in HCC cells before and after NAT10 inhibition

  • Consider enrichment strategies (e.g., immunoprecipitation with modification-specific antibodies) prior to MS analysis

• PTM induction and inhibition:

  • Use specific inhibitors or activators of enzymes responsible for different modifications

  • For example, HDAC inhibitors like LBH589 (100 nM) increase acetylation

  • Compare modification patterns before and after treatment to identify dynamic PTM sites

• Mutational analysis:

  • Generate lysine-to-arginine mutations at potential acetylation sites to prevent acetylation

  • Create serine/threonine-to-alanine mutations at phosphorylation sites

  • Express these mutants in cells and assess functional consequences

• Quantitative comparison:

  • Use quantitative methods (western blot quantification, ELISA, MS) to determine relative abundance of different modifications

  • Calculate modification ratios to assess PTM crosstalk and dynamics

What are the considerations for using Acetyl-HSP90AA1 (K292/284) antibodies in drug discovery and development for cancer therapeutics?

Using Acetyl-HSP90AA1 (K292/284) antibodies in drug discovery requires careful consideration of several factors:

• Target validation and mechanism studies:

  • Determine whether drug candidates directly affect HSP90 acetylation status

  • Assess whether acetylation at K292/284 correlates with HSP90 function and client protein stability

  • Investigate if targeting this specific modification offers therapeutic advantages over general HSP90 inhibition

• Pharmacodynamic biomarker development:

  • Validate antibodies for use in clinical sample types (blood, tumor biopsies)

  • Develop standardized protocols for sample collection, processing, and analysis

  • Establish quantitative assays (e.g., ELISA, immunohistochemistry scoring) for measuring acetylation changes in response to treatment

• Patient stratification strategies:

  • Determine whether baseline HSP90 acetylation levels correlate with response to HSP90 inhibitors

  • Investigate if acetylation patterns differ between tumor types or molecular subtypes

  • Assess whether combined analysis of HSP90 acetylation and client protein status improves predictive power

• Combination therapy rational design:

  • Use acetylation status to guide development of rational drug combinations

  • Research indicates HSP90 inhibition can sensitize tumors to immunotherapy, suggesting potential for combination approaches

  • Determine whether drugs affecting HSP90 acetylation synergize with other cancer therapies

• Resistance mechanism investigations:

  • Monitor changes in HSP90 acetylation patterns during treatment and at progression

  • Determine whether altered acetylation contributes to resistance development

  • Identify potential strategies to overcome resistance based on acetylation dynamics

• Assay validation for regulatory compliance:

  • Ensure antibody specificity meets requirements for diagnostic or companion diagnostic development

  • Validate assays according to regulatory guidelines if they will be used to make treatment decisions

  • Consider developing reference standards for acetylated HSP90 to enable cross-study comparisons

These considerations highlight the potential value of Acetyl-HSP90AA1 (K292/284) antibodies in translational research and drug development for targeting HSP90-dependent processes in cancer.